Weight loss diet and pancreas fat in type 2 diabetes
Tests an 800-calorie daily meal replacement diet in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: Pancreas Lipotoxicity in T2D: Edinburgh Diabetes Remission Study (EDRS)
Key facts
- Where
- Edinburgh, United KingdomSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 79 years old?
Source: NCT07364045, who can take part
Where in United Kingdom
- Clinical Research Facility, Royal Infirmary of EdinburghEdinburgh, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Edinburgh
- Trial code
- NCT07364045
- Record updated
- 18 June 2026
- Original description
This study aims to investigate how fat accumulation in the pancreas contributes to the development of type 2 diabetes (T2D), and how weight loss may reverse this process. Previous research has shown that reducing body weight can lead to diabetes remission, and this was accompanied by lowering intrapancreatic fat and restoration of insulin secretion, but the mechanisms behind this are not fully understood. In particular, the study aims to unravel the role of hepatic de novo lipogenesis (DNL) and lipoprotein metabolism on pancreas lipotoxicity and beta cell recovery after weight loss.Read full original descriptionShow less
Mechanisms Mediating Reversible Lipotoxicity of the Pancreas in Obesity-induced Type 2 Diabetes: Edinburgh Diabetes Remission Study (EDRS)
This study aims to investigate how fat accumulation in the pancreas contributes to the development of type 2 diabetes (T2D), and how weight loss may reverse this process. Previous research has shown that reducing body weight can lead to diabetes remission, and this was accompanied by lowering intrapancreatic fat and restoration of insulin secretion, but the mechanisms behind this are not fully understood. In particular, the study aims to unravel the role of hepatic de novo lipogenesis (DNL) and lipoprotein metabolism on pancreas lipotoxicity and beta cell recovery after weight loss.
Four groups of participants will be recruited (n=26 per group): non-diabetic, pre-diabetic, short-duration T2D (<6 years), and long-duration T2D (>10 years). Participants will be aged between 45 and 79 years and have a BMI between 30 and 45 kg/m². All participants will follow a structured weight loss programme using an 800 kcal/day Total Diet Replacement (TDR) for 8-12 weeks, followed by dietary support to maintain weight loss. The study is sponsored by NHS-Lothian and the University of Edinburgh and will be carried out at the Clinical Research Facility, Royal infirmary of Edinburgh by a specialist team (Senior Diabetes Research Nurse, Clinical Fellow, and Research Dietitian).
The primary endpoint of this study is to achieve a 10-15% reduction in body weight (~10 kg) through a low-calorie diet (800 kcal/day) to induce T2D remission and maintain this weight loss with structured dietary support for up to 6-12 months. The primary aim is to compare hepatic de novo lipogenesis-the conversion of sugar into fat by the liver-and lipoprotein export among the groups, and to examine how these parameters change in response to weight loss, improvement in metabolic status, and restoration of normal pancreatic function.
Secondary endpoints include changes in weight, HbA1c, intraorgan fat (liver/pancreas), pancreas volume and tissue characteristics, beta cell mass and function (MRI/mixed meal test), circulating blood markers (i.e. lipids, exosomes, adipokines, and inflammatory markers), and the change in adipose tissue biology (fat biopsies).
Ultimately, this study aims to understand the mechanisms of T2D remission. It will help clarify the sequence of metabolic events leading to reversible pancreatic lipotoxicity and may inform the development of new, targeted therapies for T2D.
Inclusion: Overweight/obese (BMI: 30-45 kg/m²) who have had T2D for less than 6 years or longer than 10 years, and are on treatment with diet alone or diet plus oral medication; Overweight/obese (BMI: 30-45 kg/m²) who are at pre-diabetes stage, defined as fasting blood glucose 5.6-6.9 mmol/L; Overweight/obese (BMI: 30-45 kg/m²) who are non-diabetic (control group); Age between 45 and 79 years inclusive; Post-menopausal women only (to exclude sex hormone effects on lipid metabolism); Good communication in English (able to give informed consent and follow dietary advice); Willing and able to adhere to the study protocol, including dietary intervention and scheduled follow-up visits.
Exclusion: Insulin therapy; MRI contraindications (metal implants, claustrophobia); Use of steroids or antipsychotics; Known cancer in last 5 years; History of gestational diabetes; Advanced kidney or liver disease; Allergy to local anaesthetic (for biopsy subgroup); Any disorder that may jeopardise safety or compliance; HbA1c >12% (108 mmol/mol); Weight loss >5 kg in last 6 months; Recent MI (within 6 months); First-degree relatives of people with T2D (control group); Alcohol >14 units/week; Participation in another clinical trial; Life expectancy <1 year.